» Articles » PMID: 15210610

Digitalis Therapy for Patients in Clinical Heart Failure

Overview
Journal Circulation
Date 2004 Jun 24
PMID 15210610
Citations 19
Authors
Affiliations
Soon will be listed here.
Citing Articles

Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium.

Kourek C, Briasoulis A, Papamichail A, Xanthopoulos A, Tsougos E, Farmakis D Int J Mol Sci. 2024; 25(6).

PMID: 38542088 PMC: 10969833. DOI: 10.3390/ijms25063113.


Reversing Cardiac Hypertrophy at the Source Using a Cardiac Targeting Peptide Linked to miRNA106a: Targeting Genes That Cause Cardiac Hypertrophy.

Gallicano G, Fu J, Mahapatra S, Sharma M, Dillon C, Deng C Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890169 PMC: 9317130. DOI: 10.3390/ph15070871.


Molecular docking analysis of arjunolic acid from with a coronary artery disease target APOE4.

Hazarika L, Sen S, Doshi J Bioinformation. 2022; 17(11):949-958.

PMID: 35655909 PMC: 9148589. DOI: 10.6026/97320630017949.


Medical Management of Patients With Heart Failure and Reduced Ejection Fraction.

Greenberg B Korean Circ J. 2022; 52(3):173-197.

PMID: 35257531 PMC: 8907986. DOI: 10.4070/kcj.2021.0401.


Detecting Digoxin Toxicity by Artificial Intelligence-Assisted Electrocardiography.

Chang D, Lin C, Tsao T, Lee C, Chen J, Tsai C Int J Environ Res Public Health. 2021; 18(7).

PMID: 33917563 PMC: 8038815. DOI: 10.3390/ijerph18073839.